ACE and type 2 diabetes mellitus: Although angiotensin-converting enzyme inhibitors and Ang II receptor blockers are expected to prevent type 2 diabetes and obesity-associated metabolic disorders47,48,56, this study implies that they might affect some aspects of systemic glucose metabolism through brown adipocytes and other metabolic cells.